All In Biotech

Drug Trial Radar · NCT06397313

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination With Ruxolitinib in Patients With Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

36

Actual

Start

Sep 19, 2024

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Ryvu Therapeutics SAIndustry
Sponsor type
Industry
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

Conditions

  • Myelofibrosis

Interventions

  • RVU120Drug

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

  • RuxolitinibDrug

    Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the number of participants with a response (anti-cancer activity) to RVU120 when administered as a single agent or in combination with ruxolitinibTime frame: 12 months

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Policlinico Sant'Orsola-Malpighi

    Bologna, Italy

  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

    Brescia, Italy

  • Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"

    Catania, Italy

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l.

    Meldola, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej

    Biała Podlaska, Poland

  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela

    Bydgoszcz, Poland

  • M2M Med. Sp. z o.o. Sp. j.

    Chorzów, Poland

  • Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych Faz

    Gdansk, Poland

  • Pratia Hematologia Sp. z o.o.

    Katowice, Poland

  • Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej

    Kielce, Poland

  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie

    Lublin, Poland

  • Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu

    Torun, Poland

  • Lux Med Onkologia Sp. z o.o.

    Warsaw, Poland

  • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy

    Warsaw, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

    Wroclaw, Poland

  • Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.

    Zielona Góra, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.